Download PDF
Int J Angiol
DOI: 10.1055/s-0044-1791546
Original Article

Jetstream Atherectomy with Paclitaxel-Coated Balloons: 3-Year Outcomes of the Prospective Randomized JET-RANGER Study

Nicolas W. Shammas 
1   Midwest Cardiovascular Research Foundation, Cardiovascular Research, Davenport, Iowa
,
Gail Shammas
1   Midwest Cardiovascular Research Foundation, Cardiovascular Research, Davenport, Iowa
,
Sue Jones-Miller
1   Midwest Cardiovascular Research Foundation, Cardiovascular Research, Davenport, Iowa
,
For the JET-RANGER Investigators › Author Affiliations Funding This study was funded by Boston Scientific Corporation (unrestricted grant).
› Further Information
    Permissions and Reprints

Abstract

The JET-RANGER study (NCT03206762) was a multicenter (11 U.S. centers), randomized trial, core-lab adjudicated and designed to demonstrate the superiority of Jetstream + paclitaxel-coated balloon (JET + PCB) versus percutaneous transluminal angioplasty (PTA) + PCB in treating femoropopliteal arterial disease. The 1- and 2-year outcomes have been recently published. The 3-year outcome data are presented in this report. The JET-RANGER trial initially had 47 patients with 48 lesions. Thirty-one in the JET-PCB arm and 16 in the PTA + PCB arm (2:1 randomization). At 3-year follow-ups, there were 20 patients in the JET-PCB arm and 14 patients in the PTA + PCB arm. Kaplan–Meier survival analysis was performed to estimate the freedom from target lesion revascularization (TLR) at 3 years. Bailout stenting was not considered a TLR in this analysis. Statistical significance was determined by a p-value < 0.05. Freedom from TLR was statistically similar between the two groups at 3 years between JET + PCB and PTA + PCB (freedom from TLR was 88.0 vs. 67.8%, respectively, p = 0.1380). There was also no significant difference in the change of ankle-brachial index (ABI) between the PTA + PCB and JET + PCB from baseline at 6 months (p = 0.7890), 1 year (p = 0.4070), 2 years (p = 0.7410), and 3 years (p = 0.8010). There was also no statistical difference between the JET + PCB and PTA + PCB arms for RCC improvement by one or more categories from baseline to 3 years (p = 0.8949). There were no minor or major amputations for either arm throughout the 3-year follow-up. Five JET + PCB patients died before the 3-year specified window and none in the PTA + PCB arm (p = 0.137). Two of the deaths were due to cancer and three due to cardiac causes. None were deemed related to the device or procedure. JET + PCB had similar freedom from TLR and improvement in ABI and RCC at 3-year follow-up with no difference in amputation or mortality between the 2 arms. A trend toward less TLR was seen in the JET + PCB arm.

Keywords

Jetstream - atherectomy - femoropopliteal - vessel prepping - drug-coated balloons

Note

JET-RANGER 1-year follow-up was published in Vasc Health Risk Manag 2022;18:603–615.


JET-RANGER 2-year follow-up was published in Vasc Health Risk Manag 2023;19:133–137.


Clinical Trial Registration: NCT03206762.




Publication History

Article published online:
03 October 2024

© 2024. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Dattilo R, Himmelstein SI, Cuff RF. The COMPLIANCE 360° trial: a randomized, prospective, multicenter, pilot study comparing acute and long-term results of orbital atherectomy to balloon angioplasty for calcified femoropopliteal disease. J Invasive Cardiol 2014; 26 (08) 355-360
    PubMedSearch in Google Scholar
  • 2 Shammas NW, Coiner D, Shammas GA, Dippel EJ, Christensen L, Jerin M. Percutaneous lower-extremity arterial interventions with primary balloon angioplasty versus Silverhawk atherectomy and adjunctive balloon angioplasty: randomized trial. J Vasc Interv Radiol 2011; 22 (09) 1223-1228
    CrossrefPubMedSearch in Google Scholar
  • 3 Wu Z, Huang Q, Pu H. et al. Atherectomy combined with balloon angioplasty versus balloon angioplasty alone for de novo femoropopliteal arterial diseases: a systematic review and meta-analysis of randomised controlled trials. Eur J Vasc Endovasc Surg 2021; 62 (01) 65-73
    CrossrefPubMedSearch in Google Scholar
  • 4 Gandini R, Del Giudice C, Merolla S, Morosetti D, Pampana E, Simonetti G. Treatment of chronic SFA in-stent occlusion with combined laser atherectomy and drug-eluting balloon angioplasty in patients with critical limb ischemia: a single-center, prospective, randomized study. J Endovasc Ther 2013; 20 (06) 805-814
    CrossrefPubMedSearch in Google Scholar
  • 5 Zeller T, Langhoff R, Rocha-Singh KJ. et al; DEFINITIVE AR Investigators. Directional atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis and maintain vessel patency: twelve-month results of the DEFINITIVE AR study. Circ Cardiovasc Interv 2017; 10 (09) e004848
    CrossrefPubMedSearch in Google Scholar
  • 6 Fanelli F, Cannavale A, Gazzetti M. et al. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc Intervent Radiol 2014; 37 (04) 898-907
    CrossrefPubMedSearch in Google Scholar
  • 7 Cioppa A, Stabile E, Popusoi G. et al. Combined treatment of heavy calcified femoro-popliteal lesions using directional atherectomy and a paclitaxel coated balloon: One-year single centre clinical results. Cardiovasc Revasc Med 2012; 13 (04) 219-223
    CrossrefPubMedSearch in Google Scholar
  • 8 Scheer F, Lüdtke CW, Kamusella P. et al. Combination of rotational atherothrombectomy and paclitaxel-coated angioplasty for femoropopliteal occlusion. Clin Med Insights Cardiol 2015; 8 (Suppl. 02) 43-48
    PubMedSearch in Google Scholar
  • 9 Shammas NW, Purushottam B, Shammas WJ. et al; JET-RANGER Investigators. Jetstream atherectomy followed by paclitaxel-coated balloons versus balloon angioplasty followed by paclitaxel-coated balloons: twelve-month exploratory results of the prospective randomized JET-RANGER study. Vasc Health Risk Manag 2022; 18: 603-615
    CrossrefPubMedSearch in Google Scholar
  • 10 Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2018; 7 (24) e011245
    CrossrefPubMedSearch in Google Scholar
  • 11 Shammas NW, Shammas G, Christensen L, Jones-Miller S. JET-RANGER Investigators. Jetstream atherectomy with paclitaxel-coated balloons: two-year outcome of the prospective randomized JET-RANGER study. Vasc Health Risk Manag 2023; 19: 133-137
    CrossrefPubMedSearch in Google Scholar
  • 12 Schneider PA, Varcoe RL, Secemsky E. et al. Update on paclitaxel for femoral-popliteal occlusive disease in the 15 months following a summary level meta-analysis demonstrated increased risk of late mortality and dose response to paclitaxel. J Vasc Surg 2021; 73 (01) 311-322
    CrossrefPubMedSearch in Google Scholar
  • 13 Schneider PA, Laird JR, Doros G. et al. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon. J Am Coll Cardiol 2019; 73 (20) 2550-2563
    CrossrefPubMedSearch in Google Scholar
  • 14 Schneider PA, Brodmann M, Mauri L. et al. Paclitaxel exposure: Long-term safety and effectiveness of a drug-coated balloon for claudication in pooled randomized trials. Catheter Cardiovasc Interv 2020; 96 (05) 1087-1099
    CrossrefPubMedSearch in Google Scholar
  • 15 Steiner S, Schmidt A, Zeller T. et al. COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions. Eur Heart J 2020; 41 (27) 2541-2552
    CrossrefPubMedSearch in Google Scholar
  • 16 Schroeder H, Meyer D-R, Lux B, Ruecker F, Martorana M, Duda S. Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: outcomes from the ILLUMENATE first-in-human study. Catheter Cardiovasc Interv 2015; 86 (02) 278-286
    CrossrefPubMedSearch in Google Scholar